ImmuCell Corporation (ICCC)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA 
ImmuCell Swings to Q2 Profit on Strong Sales, Shares Still Slide
ICCC posts Q2 profit on higher sales and margins, but shares fall as investors weigh one-time boosts and Re-Tain's delayed commercialization.
ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q2 2025 Earnings Conference Call August 15, 2025 9:00 AM ET Company Participants Michael F. Brigham - President, CEO, Treasurer, Secretary & Director Timothy C.
ImmuCell Upgraded to Outperform on Sales Surge & FDA Upside
ICCC earns "Outperform" rating with record Q1 sales, margin gains and growth potential tied to Re-Tain's FDA progress and new product formats.
ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains
ICCC posts record Q1 sales, returns to earnings and expands margins y/y as First Defense demand grows and production issues subside.
ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President & Chief Executive Officer Tim Fiori - Chief Financial Officer Conference Call Participants George Melas - MKH Management Russ Tolander - Capital Alliance Operator Good morning and welcome to the ImmuCell Corporation Reports First Quarter Ended March 31st, 2025 Audited Financial Results Conference Call. All participants will be in listen-only mode.
ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain
ImmuCell posts 52% y/y sales growth in Q4. It improves margins and eyes FDA approval for Re-Tain to drive expansion.
ImmuCell Corporation (ICCC) Q4 2024 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q4 2024 Earnings Conference Call February 26, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas-Kyriazi - MKH Management Operator Good morning, and welcome to ImmuCell Corporation Reports its Fourth Quarter and Year Ended December 31, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode.
Zacks Initiates Coverage of ImmuCell With Neutral Recommendation
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates ImmuCell as "Neutral." Explore ImmuCell's market leadership, growth prospects and the game-changing potential of its mastitis treatment nearing FDA approval.
ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges
ICCC sees strong Q3 sales growth but faces challenges with margins. It awaits FDA approval for its groundbreaking Re-Tain product.
ImmuCell Corporation (ICCC) Q3 2024 Earnings Call Transcript
ImmuCell Corporation (NASDAQ:ICCC ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Joe Diaz - Lytham Partners Michael Brigham - President and CEO Conference Call Participants George Melas - MKH Management Operator Good morning and welcome to ImmuCell Corporation Reports Third Quarter September 30, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode.
